Thomas Gajewski

AbbVie Foundation Professor of Pathology · University of Chicago Medical Center

Credentials: · · ·

History

Overcoming Resistance to Anti-PD1 Immunotherapy
National Cancer Institute · R35
Contact PI · $10.4M · University of Chicago
2016–2030
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $3.2M · University of Chicago
1997–2029
Host STING Pathway in Anti-Tumor Immunity
National Cancer Institute · R01
Contact PI · $983.6K · University of Chicago
2014–2019
EGR2 in T Cell Tolerance
National Cancer Institute · R01
Contact PI · $1.6M · University of Chicago
2012–2017

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
Principal investigator · Active not recruiting · Phase 2
University of Chicago
2016–2026
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2011–2015
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2006–2011
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2004